J. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)

J. Goldman & Co LP bought a new position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 232,627 shares of the company's stock, valued at approximately $1,140,000. J. Goldman & Co LP owned approximately 0.40% of Rezolute at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in RZLT. JPMorgan Chase & Co. bought a new stake in shares of Rezolute in the 3rd quarter worth $42,000. Charles Schwab Investment Management Inc. grew its stake in shares of Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after acquiring an additional 9,000 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Rezolute by 62.1% in the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock worth $316,000 after acquiring an additional 24,742 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Rezolute by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock worth $2,535,000 after acquiring an additional 25,413 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Rezolute in the 4th quarter worth $277,000. Institutional investors own 82.97% of the company's stock.

Rezolute Price Performance

NASDAQ RZLT traded up $0.01 on Friday, reaching $3.57. 1,113,556 shares of the company's stock traded hands, compared to its average volume of 629,641. Rezolute, Inc. has a 12 month low of $2.22 and a 12 month high of $6.19. The stock has a 50-day simple moving average of $3.24 and a 200 day simple moving average of $4.30. The stock has a market cap of $216.11 million, a PE ratio of -2.93 and a beta of 1.01.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). As a group, analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on RZLT. Guggenheim reissued a "buy" rating on shares of Rezolute in a report on Monday, February 10th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of Rezolute in a report on Monday, April 28th. Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a report on Wednesday. Finally, JMP Securities upped their price objective on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $12.14.

Insider Buying and Selling

In other news, CEO Nevan C. Elam acquired 12,302 shares of the stock in a transaction on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the transaction, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. This represents a 5.81% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Daron Evans acquired 10,000 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares of the company's stock, valued at approximately $687,531. This trade represents a 4.39% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 39,060 shares of company stock valued at $130,694 over the last quarter. 18.39% of the stock is owned by company insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.